Ocular Drug Delivery group (ODD)

The Ocular Drug Delivery (ODD) group develops advanced drug delivery methods for targeted and prolonged drug delivery to both the anterior and posterior segments of the eye. Furthermore, we use computational tools for drug development and preclinical-to-clinical translation to build a quantitativ...

EDCMET

01.01.2019 - 31.12.2023
Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways

Neurobiology of disease

24.10.2017 -
The main goal of our research is to understand the mechanisms that lead to neurodegenerative diseases and to identify novel therapeutic approaches for them. We are interested in the effects of environmental factors (such as air pollution and viral infections) and lifestyle factors on brain healt...

Annakaisa Haapasalo Group (Molecular Neurodegeneration)

01.06.2015 -
Our research focus lies in the genetic background and molecular mechanisms underpinning neurodegenerative diseases, especially frontotemporal dementia (FTD). To this end, we utilize a variety of in vitro and in vivo model systems and patient-derived cells, clinical samples and data. We are especi...

Sanna Kettunen

Early Stage Researcher , A.I. Virtanen Institute for Molecular Sciences

Molecular Genetics of Alzheimer's Disease

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the world, which affects up to 50% of individuals above the age of 85. Due to the global increase in the aging population, early diagnosis and treatment of AD are becoming increasingly important, not only from a human point...

Johnson Lok

Early Stage Researcher , Institute of Public Health and Clinical Nutrition